8 completed, 3 recruiting, 2 terminated, 1 active not recruiting. 8 Phase 2, 3 Phase 4, 2 Phase 1, 2 Phase 3, 1 Not applicable.
Follow crizanlizumab: new trials by email Literature Review of crizanlizumab trials Research Report on crizanlizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) Crizanlizumab, Placebo - Sickle Cell Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 354 | 2024-10-24 | 2026-10-15 |
| Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia Crizanlizumab, control - Sickle Cell Disease | Phase 1 / Phase 2 | Not yet recruiting | Children's Hospital Los Angeles | 30 | 2024-07-01 | 2023-08-30 |
| Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO], Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO] - Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System | Phase 2 | Recruiting | Sheba Medical Center | 33 | 2023-07-11 | 2025-07-22 |
| Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA Crizanlizumab - Sickle Cell Disease | Not applicable | Unknown | Andria Ford | 31 | 2022-08-01 | 2023-03-06 |
| Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India Crizanlizumab - Sickle Cell Disease | Terminated | Novartis Pharmaceuticals | 44 | 2021-11-04 | 2024-06-24 | |
| Characteristics of Patients With Sickle Cell Disease Crizanlizumab - Sickle Cell Disease | Completed | Novartis Pharmaceuticals | 540 | 2021-08-30 | 2022-11-08 | |
| An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients crizanlizumab - Sickle Cell Disease (SCD) | Phase 4 | Completed | Novartis Pharmaceuticals | 140 | 2021-07-14 | 2025-09-26 |
| Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study Crizanlizumab - Sickle Cell Disease | Phase 4 | Recruiting | Novartis Pharmaceuticals | 130 | 2021-06-10 | 2026-06-08 |
| Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL) Crizanlizumab - RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy | Phase 2 | Completed | Washington University School of Medicine | 18 | 2021-01-25 | 2026-04-23 |
| Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE theraputic heparin, prophylactic heparin, P2Y12 - Covid19 | Phase 4 | Completed | Matthew Neal MD | 3591 | 2020-09-04 | 2024-12-30 |
| Crizanlizumab for Treating COVID-19 Vasculopathy Crizanlizumab, 0.9% saline - COVID-19 | Phase 2 | Completed | Johns Hopkins University | 54 | 2020-07-09 | 2021-11-09 |
| A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism Crizanlizumab - Priapism | Phase 2 | Completed | Novartis Pharmaceuticals | 36 | 2019-10-16 | 2026-01-13 |
| Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Ruxolitinib, Siremadlin, Crizanlizumab - Myelofibrosis | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 45 | 2019-09-26 | 2025-08-07 |
| Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients Crizanlizumab (SEG101), Placebo - Sickle Cell Disease (SCD) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 253 | 2019-07-26 | 2026-10-14 |
| Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients Crizanlizumab - Sickle Cell Disease (SCD) | Phase 2 | Completed | Novartis Pharmaceuticals | 117 | 2018-10-01 | 2025-10-16 |
| Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC) crizanlizumab - Sickle Cell Disease (SCD) | Phase 2 | Completed | Novartis Pharmaceuticals | 57 | 2017-12-19 | 2024-10-09 |
| Managed Access Programs for SEG101, Crizanlizumab crizanlizumab - Sickle Cell Disease | Available | Novartis Pharmaceuticals | 2026-04-14 |
Anemia, Sickle Cell (12) · Vaso-Occlusive Crises (5) · COVID-19 (3) · Hematologic Diseases (2) · Hemoglobin SC Disease (2) · Sickle Cell Trait (2) · Coronavirus Infections (1) · Priapism (1) · Primary Myelofibrosis (1) · Vasculopathy, Retinal, With Cerebral Leukodystrophy (1)
Novartis Pharmaceuticals (11) · Andria Ford (1) · Children's Hospital Los Angeles (1) · Johns Hopkins University (1) · Matthew Neal MD (1) · Sheba Medical Center (1) · Washington University School of Medicine (1)
United States (11) · Brazil (5) · Italy (5) · Spain (5) · Colombia (4) · Germany (4) · Turkey (Türkiye) (4) · Belgium (3) · Canada (3) · France (3) · India (3) · Lebanon (3) · Oman (3) · United Kingdom (3) · Netherlands (2)
Andria Ford, MD (1) · Charles J Lowenstein, MD (1) · Jeffrey Berger, MD (1) · Jon Detterich (1) · Judith Hochman, MD (1) · Mikhail Kosiborod, MD (1) · Ronnie Shapira Frommer, Dr (1) · Scott Solomon, MD (1)
PMID 33186055, PMID 33502773, PMID 34473343, PMID 34904132, PMID 34922648, PMID 36355805, PMID 36529836, PMID 36942550, PMID 37227729, PMID 37254256, PMID 37356038, PMID 37489818, PMID 37979717, PMID 38950286, PMID 39250922, PMID 39473076, PMID 39497751, PMID 40088922, PMID 40334082, PMID 42089155
2017 (2), 1OT2HL156812-01 (1), 2019 (1)